en · de · es · fr · pt
aod-9604-notes.peptides4800.com › Info › Handling, Analysis, And Quality Control — Background and Details

Handling, Analysis, And Quality Control — Background and Details

By Editorial Desk · published 2026-05-24 · last reviewed 2026-06-26 · Info

AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-06-26 and is reviewed periodically as new material appears.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; visual inspection
SolubilitySoluble in water and aqueous buffersDepends on pH, purity, and counterion
Typical storage-20 °C or below, desiccatedProtect from light; avoid repeated freeze-thaw after reconstitution
Common analytical methodReversed-phase HPLC and mass spectrometryPurity by HPLC; identity and mass by LC-MS or MALDI-TOF
Common synonymshGH fragment 176–191; AOD-9604Names vary in research and product labeling

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Related pages on this site

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Notes from published material

Diffusion pumps blow out gas molecules with jets of an oil or mercury vapor, while turbomolecular pumps use high speed fans to push the gas. Both of these pumps will stall and fail to pump if exhausted directly to atmospheric pressure, so they must be exhausted to a lower grade vacuum created by a mechanical pump, in this case called a backing pump. As with positive displacement pumps, the base pressure will be reached when leakage, outgassing, and backstreaming equal the pump speed, but now minimizing leakage and outgassing to a level comparable to backstreaming becomes much more difficult.

=== Mass analysis === Fragmentation caused by ETD allows more complete protein sequence information to be obtained from ETD spectra than from CID tandem mass spectrometry. Because many peptide backbone c- and z- type ions are detected, almost complete sequence coverage of many peptides can be discerned from ETD fragmentation spectra. Sequences of 15-40 amino acids at both the N-terminus and the C-terminus of the protein can be read using mass-to-charge values for the singly and doubly charged ions. These sequences, together with the measured mass of the intact protein, can be compared to database entries for known proteins and to reveal post-translational modifications.

=== European Union === In 2014, Galloway said he would "be campaigning to remain in the European Union, as anyone with any brain cells will also be doing". However, in 2016, he began campaigning for the UK to leave the EU. At a rally at the Queen Elizabeth II Conference Centre on 19 February 2016, Galloway endorsed the Grassroots Out (GO) campaign for the European Union membership referendum. He was introduced by UKIP leader Nigel Farage as a "special guest" who is "without doubt one of the greatest orators in this country, he is a towering figure on the left of British politics". Galloway's presence at the rally prompted some of those present to leave. Labour MP Kate Hoey, who was involved with GO, defended Galloway's participation. "George ended up getting a hugely favourable response to what he said". Responding to criticism of his association with Farage, Galloway tweeted: "We are not pals. We are allies in one cause. Like Churchill and Stalin". On 17 April 2019 Galloway announced he would support the Brexit Party led by Nigel Farage in the May 2019 European Parliament election. He said that "given the nature of Labour's Euro-fanatic candidates list and the crucial juncture we have reached in the fight for the full implementation of the Brexit referendum result and for one-time only I will be supporting Nigel Farage in next months elections."

Sources: en.wikipedia.org

Further detail

1993/616) Magistrates' Courts (Reciprocal Enforcement of Maintenance Orders) (Miscellaneous Amendments) Rules 1993 (S.I. 1993/617) Maintenance Orders (Reciprocal Enforcement) Act 1992 (Commencement) Order 1993 (S.I. 1993/618) Public Trustee (Fees) (Amendment) Order 1993 (S.I. 1993/619) Child Maintenance (Written Agreements) Order 1993 (S.I. 1993/620) Children (Admissibility of Hearsay Evidence) Order 1993 (S.I. 1993/621) High Court (Distribution of Business) Order 1993 (S.I. 1993/622) Maintenance Orders (Backdating) Order 1993 (S.I. 1993/623) Children (Allocation of Proceedings) (Amendment) Order 1993 (S.I. 1993/624) Education (Listed Bodies) Order 1993 (S.I. 1993/625) Education (Recognised Bodies) Order 1993 (S.I. 1993/626) Family Proceedings Courts (Child Support Act 1991) Rules 1993 (S.I. 1993/627) Education (Queen Elizabeth Atherstone Further Education Corporation) (Dissolution) Order 1993 (S.I. 1993/628) National Board for Nursing, Midwifery and Health Visiting for England (Constitution and Administration) Order 1993 (S.I. 1993/629) Motor Vehicles (Type Approval and Approval Marks) (Fees) Regulations 1993 (S.I. 1993/630) A65 Trunk Road (Hellifield and Long Preston Bypass and Slip Roads) Order 1993 (S.I. 1993/631) A65 Trunk Road (Bigholmes Lane to Switchers) (Detrunking) Order 1993 (S.I. 1993/632) National Board for Nursing, Midwifery and Health Visiting for Scotland Order 1993 (S.I. 1993/637) Lothian and Central Regions and West Lothian and Falkirk Districts (Mannerston/Cauldcoats Holdings and M9 Motorway) Boundaries Amendment Order 1993 (S.I.

Potassium alum is used in medicine mainly as an astringent (or styptic) and antiseptic. Styptic pencils are rods composed of potassium alum or aluminum sulfate, used topically to reduce bleeding in minor cuts (especially from shaving) and abrasions, nosebleeds, and hemorrhoids, and to relieve pain from stings and bites. Potassium alum blocks are rubbed over the wet skin after shaving. Potassium alum is also used topically to remove pimples and acne, and to cauterize aphthous ulcers in the mouth and canker sores, as it has a significant drying effect to the area and reduces the irritation felt at the site. It has been used to stop bleeding in cases of hemorrhagic cystitis and is used in some countries as a cure for hyperhidrosis. It is used in dentistry (especially in gingival retraction cords) because of its astringent and hemostatic properties. Potassium and ammonium alum are the active ingredients in some antiperspirants and deodorants, acting by inhibiting the growth of the bacteria responsible for body odor. Alum's antiperspirant and antibacterial properties contribute to its traditional use as an underarm deodorant. It has been used for this purpose in Europe, Mexico, Thailand (where it is called sarn-som), throughout Asia and in the Philippines (where it is called tawas). Today, potassium or ammonium alum is sold commercially for this purpose as a "deodorant crystal". Beginning in 2005 the US Food and Drug Administration no longer recognized it as a wetness reducer, but it is still available and used in several other countries, primarily in Asia.

== Properties == These enzymes are acid proteases; eqolisin for example is most active at pH 2.0 when casein is used as substrate. Eqolosins prefer bulky amino acid residues at the P1 site and small amino acid residues at the P1′ site. A characteristic of the protease is its insensitivity to pepstatin and S-PI (acetyl pepstatin) and it was previously classed as "pepstatin-insensitive carboxyl proteinases". The other "pepstatin-insensitive carboxyl proteinases" belongs to subfamily of serine protease, serine-carboxyl protease (sedolisin) which was discovered in 2001. These proteases are also not inhibited by DAN (diazoacetyl-DL-norleucine methylester) (7) but may be inhibited by EPNP (1,2-epoxy-3-(p-nitrophenoxy) propane).

Sources: en.wikipedia.org

Frequently asked questions

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

What methods confirm AOD9604 identity?

Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.

Is AOD9604 the same as human growth hormone?

No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network